All News

The Food and Drug Administration approved Blenrep to treat patients with relapsed/refractory multiple myeloma.

Dr. Othman Al-Sawaf discusses the encouraging long-term data that makes the Venclexta-Gazyva combination a viable treatment option for patients with CLL.

Even though I knew I was eligible for COBRA and that it would come into effect soon, my anxiety soared and grew as the days progressed. I told anybody who would listen that a cancer survivor in the time of COVID cannot be without insurance for even a second.

“Final results from ASCEND confirm the findings of the interim analysis and support the favorable efficacy and safety of (Calquence) versus standard-of-care regimens in relapsed or refractory CLL,” said Dr. Paolo Ghia.

The FDA’s fast track designation for BST-236 to treat adults aged 75 years or older with acute myeloid leukemia, or who have comorbidities that prevent the use of intensive induction chemotherapy, may open the doors to an accelerated approval.

A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa.

“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.

A colon cancer survivor reflects on receiving her first diagnosis as a high school student, and offers current students whose academic careers have been altered by COVID-19 some advice on how they'll get through the missed experiences.

A patient assessment tool, known as the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu), was a viable and valid outcome measure for patients with acute myeloid leukemia not eligible for intensive therapy.

On social media, CURE® recently asked its readers to share the advice they would give someone looking to help a friend or loved one with cancer. Here, we share some of their responses.

A roundup of the latest news and updates for patients with ovarian cancer from CURE®.

An 11-year survivor of inflammatory breast cancer details how even though she considers herself one of the lucky ones, the awareness that “as far as we know” could change in one blinding moment still haunts her.

The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for July 2020.

A metastatic breast cancer survivor notes that It takes bravery to choose friends with cancer, but she stresses that the love and joy that comes with those friendships far outweigh the potential grief.

There aren't many upsides to getting diagnosed with pancreatic cancer, except for the fact that I lost 100 pounds and now look good in skinny jeans.

The Food and Drug Administration approved Monjuvi in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

I asked fellow patients with cancer and survivors on Twitter for advice on coping strategies to combat "Scanxiety" and some suggested making a conscious attempt to not let anxiety ruin the days leading up to your next scan. I gave it a shot, and it worked.

From a new survey showing that more than one-third of Americans missed cancer screenings due to COVID-19 fears to a couple overcoming both COVID-19 and breast cancer, here’s what’s making the headlines in the cancer space this week.

The Food and Drug Administration has approved Tecentriq in combination with Cotellic and Zelboraf for the treatment of patients with BRAF V600 mutation-positive advanced melanoma.

A list of the recent trial initiations that occurred within the cancer space in July.

A 10-year breast cancer, and six-year melanoma survivor reassures other survivors that they are not alone if they are struggling with anxiety, depression or PTSD years after their cancer treatments have ended.

Lung cancer survivors stage a takeover of Lung Cancer Foundation of America’s social media channels on World Lung Cancer Day August 1 to demonstrate what it means to be #livingwithlungcancer.

Save the date! We invite you to join CURE® for our next monthly #CureConnect Tweet Chat on Thursday, July 30, at 1 p.m. EST, to discuss cancer survivorship and all it entails.

The use of a mobility aide program in a cancer unit among the Mount Sinai Health System helped 76% of patients hospitalized for their cancer either maintain or improve their mobility scores, helping to reduce excess days spent in the hospital and readmission rates.

As I walk around the senior community that I live in, I notice the stark reminders that life is an impermanent adventure.

The results of an ongoing study designed to reveal genetic characteristics linked with the development of cholangiocarcinoma could pave the way for more accurate prognoses, as well as new treatments.

The microorganisms inside a patient's gastrointestinal tract may have a role to play in how immunotherapy can treat certain types of cancer.